Table 5 Multivariate analysis of the factors affecting IFN α-2b therapeutic efficacy
Prognostic factors | Regression coefficent | Standard error | Z value | P value | OR value | 95% confidence interval |
|---|---|---|---|---|---|---|
Age | 1.03 | 0.77 | 1.33 | 0.18 | 2.80 | [-0.48~2.54] |
Gender | 0.32 | 0.55 | 0.58 | 0.03 | 1.37 | [0.75~1.39] |
Genotype (A/B/C) | 0.96 | 0.27 | 3.51 | 0.04 | 2.62 | [0.73~1.50] |
HBeAg (+/–) | 0.86 | 0.31 | 2.80 | 0.75 | 2.37 | [-0.26~1.47] |
HBeAb (+/–) | -0.80 | 0.27 | -2.92 | 0.63 | 0.45 | [-1.34~1.27] |
ALT (IU/L) | -0.58 | 0.32 | -1.82 | 0.07 | 0.56 | [-1.21~0.05] |
AST (IU/L) | -1.93 | 0.34 | -5.65 | 0.96 | 0.14 | [-2.60~1.26] |
ALB (g/L) | 0.17 | 0.77 | 0.22 | 0.83 | 1.62 | [-1.35~1.68] |
TBIL (mg/dL) | 0.001 | 0.004 | 1.40 | 0.16 | 1.00 | [1.00~1.24] |
CHE (U/L) | 2.18 | 1.23 | 1.78 | 0.08 | 8.91 | [0.80-99.22] |
CREA (mg/dL) | -0.04 | 0.03 | -1.55 | 0.12 | 0.96 | [0.91~1.01] |
INR for PT | -0.003 | 0.001 | -1.94 | 0.05 | 0.99 | [0.99~1.00] |
HBV-DNA | 0.003 | 0.001 | 2.03 | 0.04 | 1.00 | [1.00~1.01] |
SOCS-1 | -3.67 | 1.49 | -2.47 | 0.03 | 0.03 | [0.01~0.47] |
SOCS-3 | -2.50 | 1.24 | -2.02 | 0.04 | 0.08 | [0.01~0.93] |
Cons | -0.11 | 4.07 | -0.03 | 0.98 | — | — |